Abstract: GBM is characterized by intratumoral heterogeneity. Tumor heterogeneity, clonal diversity and mutation acquisition hamper the ability to tailor personalized therapy for GBM. Tumor sampling has limited ability to accurately capture the molecular landscape of the tumor and to disclose acquired molecular aberrations. Mutation analysis of cfDNA is a non-invasive procedure which may overcome these limitations as it may reflect the real composition of the tumor and track the molecular evolution. We sequenced cfDNA of GBM patients and assessed mutation patterns and fusion genes. METHODS: We collected blood and respective tumor samples from 27 GBM patients and blood samples from 14 healthy controls. Tumor DNA, cfDNA and WBC DNA were sequenced using deep sequencing procedures. The data were analyzed for detection of single nucleotide polymorphism (SNPs) and gene-gene fusions. RESULTS:GBM cfDNA concentrations were significantly elevated (median: 23.63 ng/mL; range 12.6–137) compared to healthy controls (median 2.06; range 1.68–7.62) (p < 0.0001). We identified unique SNPs in each glioma patient’s cfDNA and the corresponding tumor DNA including the top-10 most frequently mutated genes in GBM. For example, mutation of TP53.

Bioinfo4Women seminars / Virtual BSC RS

Venue: Online seminar - Zoom

Date: 02/12/2020

Time: 11:00 (CET)

Host: Barcelona Supercomputing Center

A novel liquid biopsy platform utilizes gene-gene fusions for high-grade glioma patients


Milana Frenkel-Morgenstern

Head of the “Cancer Genomics and BioComputing in Complex Diseases” group in the Azrieli faculty of Medicine, Bar-Ilan University

Pin It on Pinterest